Full-Time
Global biopharma researching, developing, delivering medicines
$239.1k - $289.7k/yr
Company Historically Provides H1B Sponsorship
Summit, NJ, USA + 1 more
More locations: Princeton, NJ, USA
In Person
On-site in Madison, NJ or Princeton, NJ.
Bachelor's, MBA
See people who can refer or advise you
Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1887
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Hybrid Work Options
Professional Development Budget
Bristol Myers Squibb will build a $2.3 billion drug manufacturing campus in Houston, Texas, as part of its $40 billion US investment commitment over five years. The 600,000-square-foot facility at Generation Park will produce small molecules, biologics, and antibody-drug conjugates. The campus will employ nearly 500 people in operations, production, engineering, quality control, and administration. Construction is expected to support roughly 2,000 workers through 2030 before operations fully launch. Texas Governor Greg Abbott announced Bristol Myers is eligible for a $4.89 million grant through the Texas Enterprise Fund. The company selected Houston after evaluating multiple markets, citing workforce availability in life sciences, incentives, and infrastructure proximity. Bristol Myers raised its full-year revenue forecast to approximately $49 billion to $50 billion earlier this year.
Bristol Myers Squibb announced an expanded partnership with Nvidia to build what it claims will be "the most powerful and energy-efficient single-owned Nvidia infrastructure in life sciences". BMS joins Eli Lilly and Roche in staking supercomputer superlative claims, though companies use different metrics to measure power. According to Nvidia, BMS' planned system will be the most advanced by operations per second, whilst others measure by GPU count or single system capacity. The companies are pursuing greater computing power to train larger models, run more complex experiments, and accelerate drug discovery. BMS has worked with Nvidia for nearly three years. The company previously used AI to overcome a plateau whilst searching for a clinical candidate for a sickle cell programme. Under the expanded deal, BMS will deploy Nvidia's DGX SuperPOD supercomputer, delivering up to ten times greater performance per megawatt than its predecessor.
Schrödinger has announced a strategic collaboration with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, within BMS's research organisation. The agreement expands upon their existing partnership, enabling BMS scientists to explore more scientific possibilities and accelerate discovery decisions. Under the collaboration, Schrödinger will work with BMS scientists to develop novel functionality within Bunsen alongside its computational technologies and RetroSynth AI-driven synthesis planning platform. Unlike general-purpose agents, Bunsen is optimised to execute Schrödinger's physics-based computational platform by planning and running complex molecular discovery workflows. The deployment allows BMS to scale its predict-first computational approach across a broader group of scientists, helping them navigate molecular design space more efficiently in discovering innovative medicines.
AstraZeneca and Bristol Myers Squibb have held initial discussions about a potential merger that would create a combined entity worth nearly $400 billion, according to reports citing people familiar with the matter. The market reaction was sharply negative, with AstraZeneca shares falling more than 8%, wiping out roughly $22 billion in market value, whilst Bristol Myers dropped almost 1.5%. The deal would strengthen AstraZeneca's cancer and cardiovascular drug portfolios, which accounted for 44% and 22% respectively of its $59 billion revenue last year. Bristol Myers faces upcoming patent losses for key drugs including immunotherapy Opdivo and blood thinner Eliquis. Analysts questioned the strategic rationale, noting AstraZeneca's recent success under CEO Pascal Soriot.
AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports. By Reuters Reuters Updated August 2, 2026 4:05 PM Gift Article Aug 2 (Reuters) - UK drugmaker AstraZeneca has been exploring a deal to combine with U.S. rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter. The deal could create one of the world's biggest pharmaceutical companies with a combined value of nearly $400 billion. The companies have held talks on a potential tie-up in recent months, the report said, adding that a deal could materialize soon, but could also be delayed or fall apart. Reuters could not immediately verify the report. AstraZeneca declined to comment, while Bristol Myers did not immediately respond to a Reuters request for comment. Last year, AstraZeneca unveiled plans for a direct U.S. listing, aiming to capitalize on stronger valuations in the U.S. market while remaining listed in London. STRONG GROWTH IN CANCER DRUGS AstraZeneca's share price has more than quadrupled during Pascal Soriot's 14-year tenure as CEO, soaring above the wider FTSE 100 index and main British rival GSK. Second-quarter results last week showed strong demand for cancer and rare disease drugs continues to drive growth. Cancer treatments accounted for about $25 billion in 2025 sales, nearly half of the total, followed by cardiovascular, renal and metabolism treatments worth about $12 billion. Combining with Bristol Myers, whose shares are up around 44% over the last year, could draw attention from antitrust regulators. Oncology drugs accounted for over 40% of its overall sales in the first six months of 2026, and the two companies' cancer immunotherapies directly compete. "I would expect a Trump FTC to scrutinize the merger and if there are significant overlaps in certain drugs and late stage pipeline overlaps it would require meaningful divestitures," said antitrust lawyer Andre Barlow with DBM Law Group, referring to the U.S. Federal Trade Commission. Bristol Myers has been doing smaller deals to gain new drugs as it faces declining sales of older medicines, some of which will soon face generic competition. In 2019, Bristol Myers bought Celgene for about $80 billion, acquiring its flagship blood cancer drug Revlimid, which became Bristol's top-selling product. Revlimid has already lost patent protection and its current top sellers - cancer immunotherapy Opdivo and blood thinner Eliquis - could lose patent protection by 2028. Barlow noted that in the deal for Celgene, the Trump FTC required Celgene to sell psoriasis treatment Otezla, a major divestiture at $13.4 billion. "There is bipartisan support to scrutinize pharma deals so I would imagine that even the Trump FTC would ask the broader questions relating to bundling of products and a lack of future innovation, in addition to scrutinizing all direct overlaps," he said. Bristol raised its full-year revenue and profit forecast last week as strong sales of Eliquis and newer medicines pushed second-quarter results well past analysts' estimates. Its promising newer drugs and pipeline assets include an experimental blood thinner milvexian, anemia treatment Reblozyl and heart drug Camzyos. The report of the potential deal comes about a dozen years after AstraZeneca fended off a takeover attempt by larger U.S. rival Pfizer. Large pharma deals have been rare in recent years, in part due to concerns about antitrust and U.S. pressure to keep drug prices low. Besides Bristol and Celgene, AbbVie bought Allergan in 2020 and Takeda and Shire combined in 2019. (Reporting by Devika Nair in Bengaluru and Michael Erman in New Jersey; Additional reporting by Chris Sanders in Washington; Editing by Caroline Humer and Bill Berkrot) This story was originally published August 2, 2026 at 12:36 PM.